Negaban (temocillin) / Eumedica - LARVOL DELTA

In Vitro Efficacy of Cephamycins and Temocillin against ESBL Enterobacterales Clinical Isolates (IDWeek 2026) - No abstract available

Preclinical • Infectious Disease

Subcutaneous Ertapenem and Temocillin for Symptom Control of Pelvic Collection in the Palliative Care Setting: A Case Report. (PubMed, Cureus) - "Subcutaneous ertapenem, followed by temocillin, resulted in marked symptomatic improvement and was well tolerated with infusion rate adjustments.  This intervention led to a significant improvement in quality of life, enabling over four months at home and the achievement of important personal milestones. This case highlights the potential role of subcutaneous antibiotics for symptom control in palliative care and underscores the need for further consensus guidance."

Journal • Infectious Disease • Oncology • Pain • Palliative care

Rapid MALDI-TOF MS antimicrobial susceptibility testing with the MBT FAST assay. (PubMed, J Clin Microbiol) - "Essential agreement (EA), defined as MICs within ±1 two-fold dilution step of the standard method, was as follows: amoxicillin/clavulanic acid 96.3%, amikacin 97.5%, aztreonam 95.5%, ceftazidime/avibactam 95.5%, ceftazidime 94.6%, cefepime 92.2%, ciprofloxacin 91.8%, colistin 92.2%, ceftriaxone 95.5%, cefotaxime 94.2%, gentamicin 95.5%, imipenem 91.8%, levofloxacin 97.9%, meropenem 87.2%, meropenem/vaborbactam 94.2%, piperacillin/tazobactam 90.9%, trimethoprim/sulfamethoxazole 90.9%, temocillin 93.3%, and tobramycin 97.5%. In a diverse collection of Enterobacteriaceae tested against a panel of 19 antibiotics, the assay provided reliable minimum inhibitory concentration results after 6 h and showed high agreement with standard broth microdilution. Because MALDI-TOF MS instruments are widely used in clinical microbiology laboratories, this approach could make rapid phenotypic susceptibility testing easier to integrate into routine workflows."

Journal

Head-to-head in vitro susceptibility comparison of temocillin with amoxicillin/clavulanate, piperacillin/tazobactam and meropenem among Enterobacterales isolates in a UK district general hospital. (PubMed, Eur J Clin Microbiol Infect Dis) - "Temocillin demonstrated high in vitro activity and outperformed amoxicillin/clavulanate while showing comparable activity to piperacillin-tazobactam. Its retained activity in multidrug resistant isolates supports its potential role as a carbapenem-sparing option in antimicrobial stewardship."

Head-to-Head • Journal • Preclinical • Infectious Disease

Antibiotic resistance and molecular characteristics of OXA-48-producing Klebsiella pneumoniae isolates from northeastern Poland. (PubMed, Adv Clin Exp Med) - "Two sequence types of K. pneumoniae, ST15 and ST2193, producing OXA-48 carbapenemase and exhibiting resistance to aminoglycosides and fluoroquinolones associated with the aac(6')-Ib, aph(3")-Ib, and qnrS genes, respectively, were identified."

Journal • Infectious Disease • Pneumonia

Cost, availability and affordability of antibiotics in Islamic Republic of Iran. (PubMed, East Mediterr Health J) - "Among the injectables, streptomycin was the cheapest (15 000 IRR/defined daily dose), followed by procaine-benzylpenicillin (82 325 IRR/defined daily dose), while temocillin was the most expensive (25 828 000 IRR/defined daily dose)...Among the orals, nitrofurantoin was the cheapest (12 370 IRR/defined daily dose) while linezolid was the most expensive (1 030 558 IRR/defined daily dose)...Our findings show that although access antibiotics remain largely affordable, watch group antibiotics were used excessively. Targeted policies are needed on the pricing, production, distribution, and prescription of antibiotics in Islamic Republic of Iran to promote rational use and curb antimicrobial resistance."

Journal

Temocillin versus carbapenems for bacteraemia due to third-generation cephalosporin-resistant Enterobacterales in Spain (ASTARTÉ): a multicentre, phase 3, open-label, non-inferiority, randomised clinical trial. (PubMed, Lancet) - P3 | "In patients with bacteraemia caused by 3GCR-E, temocillin was non-inferior to carbapenems as targeted treatment. These findings support the use of temocillin as an effective and safe alternative to carbapenems in this setting."

Head-to-Head • Journal • P3 data • Infectious Disease

Temocillin as a carbapenem-sparing option for ESBL bloodstream infection. (PubMed, Lancet) - No abstract available

Journal • Infectious Disease

Diagnostic Performance of Combination Disk and CIM Tests for Carbapenemase Detection in Enterobacterales Compared with Real-Time Multiplex PCR. (PubMed, Infect Dis Clin Microbiol) - "The combination disk method, including temocillin resistance and ethylenediaminetetraacetic acid (EDTA)-based evaluation, showed strong performance in predicting OXA-48- and NDM-associated carbapenemases. However, in endemic regions, phenotypic results should ideally be confirmed by molecular methods."

Journal • Infectious Disease • Pneumonia

TEMTtoGo: Efficacy of Temocillin Compared to Standard of Care in the Treatment of Neisseria Gonorrhoeae Infections (clinicaltrials.gov) - P3 | N=360 | Not yet recruiting | Sponsor: Assistance Publique - Hôpitaux de Paris

Head-to-Head • New P3 trial • Infectious Disease

Evaluation of new expert rules for the detection and differentiation of carbapenemase-producing Enterobacterales within the French epidemiological context. (PubMed, J Clin Microbiol) - "In Europe, the emergence of OXA-48-like variants such as OXA-244 and OXA-484, which exhibit low hydrolytic activity to carbapenems and temocillin, complicates routine phenotypic detection and may lead to diagnostic failure...We demonstrate that this integrated approach provides accurate and rapid screening, with good performance for carbapenemase class prediction, particularly for NDM and KPC producers. The implementation of a dedicated rule significantly improves detection of difficult-to-identify OXA-244/OXA-484 producers, addressing an important diagnostic gap."

Journal • Infectious Disease

APHP251262: Efficacy of Temocillin compared to standard of care in the Treatment of Neisseria gonorrhoeae Infections: A Multicenter Randomized Controlled Non-Inferiority Trial (TEMtoGo). (clinicaltrialsregister.eu) - P2/3 | N=360 | Not yet recruiting | Sponsor: Assistance Publique Hopitaux De Paris

Head-to-Head • New P2/3 trial • Infectious Disease

Temocillin efficacy and emergence of resistance in Enterobacter cloacae Complex in a murine peritonitis model. (PubMed, J Antimicrob Chemother) - "Rapid and frequent emergence of resistant mutants to TEM was evidenced in vitro for distinct TEM-susceptible ECC strains. This led to TEM inefficacy in a high-inoculum peritonitis model with TEM_S E. asburiae. TEM should be used with caution for the treatment of severe ECC infections, even against susceptible strains."

Journal • Preclinical • Infectious Disease

Improved hydrolysis of piperacillin by OXA-48-like R214G variants, a selective advantage under piperacillin-tazobactam exposure. (PubMed, Antimicrob Agents Chemother) - "Among them, OXA-244 (OXA-48-R214G) and OXA-484 (OXA-181-R214G) are increasingly reported, despite overall reduced hydrolytic activities for β-lactams, including temocillin and carbapenems. The addition of NaHCO3 raised the activity and thermal stability of all enzymes, especially of OXA-48, which appeared more sensitive to the presence of NaHCO3. Although OXA-48-like R214G is considered a loss-of-function variant, our findings indicate it exhibits increased hydrolytic activity toward piperacillin, which may result in an advantage under piperacillin-tazobactam exposure and thus could contribute to the selection of these globally expanding variants."

Journal

Temocillin: a therapeutic alternative in bone and joint infections due to third generation cephalosporin-resistant Enterobacterales? (PubMed, J Antimicrob Chemother) - "This study demonstrated the high in vitro efficacy of temocillin against 3GC-R Enterobacterales from BJIs, regardless of the underlying resistance mechanism. However, dosage adjustments based on the strain's MIC and the patient's renal function are crucial for optimal efficacy."

Journal • Infectious Disease

Temocillin vs carbapenems for the targeted treatment of bacteraemia due to third-generation cephalosporin-resistant Enterobacterales: DOOR and subgroups analysis of ASTARTÉ pragmatic trial (ESCMID Global 2026) - No abstract available

In vitro activity of temocillin alone and in combination with avibactam against carbepenemase-producing Klebsiella pneumoniae strains (ESCMID Global 2026) - No abstract available

Combination therapy • Preclinical • Infectious Disease • Pneumonia

Exploring carbapenem-sparing strategies: in vitro susceptibility analysis of temocillin and cefepime against Enterobacterales bloodstream isolates (ESCMID Global 2026) - No abstract available

Preclinical

Head-to-head in vitro susceptibility comparison of temocillin with co-amoxiclav, piperacillin/tazobactam and meropenem among Enterobacterales isolates in a UK district general hospital (ESCMID Global 2026) - No abstract available

Head-to-Head • Preclinical

In vitro activity of temocillin alone and in combination with amikacin against MDR K. pneumoniae strains: reversal of phenotypic resistance (ESCMID Global 2026) - No abstract available

Combination therapy • Preclinical • Infectious Disease • Pneumonia

Investigating temocillin resistance amongst Gram-negative isolates from renal patients within a tertiary London teaching hospital (ESCMID Global 2026) - No abstract available

Clinical • Gram negative • Infectious Disease

Evaluation of MIC and clinical response to temocillin in a university transplant centre (ESCMID Global 2026) - No abstract available

Clinical • Transplantation

Synergistic activity of fosfomycin and temocillin against GES carbapenemase-producing Enterobacteriaceae (ESCMID Global 2026) - No abstract available

Pharmacodynamics of temocillin: fT>MIC targets from an in vitro pharmacokinetic model of infection in comparison to murine thigh and lung infection models (ESCMID Global 2026) - No abstract available

PK/PD data • Preclinical • Infectious Disease • Respiratory Diseases

Pharmacokinetic modelling of temocillin in children with urinary tract infections (ESCMID Global 2026) - No abstract available

Clinical • PK/PD data • Infectious Disease • Nephrology